CSL acquires option to Pevion's candidiasis vaccine

In the first deal for the product, CSL has acquired the right of first refusal to a licence to commercialise Pevion Biotech's therapeutic vaccine against Candida albicans, PEV7, in Australia and New Zealand.

In the first deal for the product, CSL has acquired the right of first refusal to a licence to commercialise Pevion Biotech's therapeutic vaccine against Candida albicans, PEV7, in Australia and New Zealand.

The two companies have also entered into an agreement for the supply of certain components of Pevion's virosomal vaccines, although...

Welcome to Scrip

Create an account to read this article

More from Anti-infective

Gilead’s Yeytuo, Lilly’s Kisunla Headline CHMP Positive Opinions

 

Yeytuo will have remaining challenges to PrEP to overcome, while Kisunla’s label reflects dosing titration data from a Phase IIIb study to mitigate ARIA-E.

Memo Therapeutics Plans BK Virus Therapy Phase III Despite Trial Miss

 
• By 

Pointing to data that show a benefit in reducing viral load and the histological signs of the infection, Memo says its drug, potravitug, could become the first therapy to treat BK polyomavirus in kidney transplant recipients.

Moderna’s Spikevax Wins Pediatric Approval, But With Narrower Label

 

The approval for young children, consistent with the FDA’s new COVID-19 vaccine policy, restricts Spikevax to those with conditions putting them at higher risk.

Four Chinese Firms Snag Global First-In-Class Approvals In China

 

Four Chinese companies have won approvals in China, the first anywhere, for novel drugs for diffuse large B-cell lymphoma, certain types of non-small cell lung cancer and influenza A.

More from Therapeutic Category

More Pressure on Elevidys As The EU’s CHMP Says ‘No’

 

Just days after Roche stopped shipments of the DMD gene therapy following safety concerns raised by two patient deaths, its EU approval application has hit a block.

Memo Therapeutics Plans BK Virus Therapy Phase III Despite Trial Miss

 
• By 

Pointing to data that show a benefit in reducing viral load and the histological signs of the infection, Memo says its drug, potravitug, could become the first therapy to treat BK polyomavirus in kidney transplant recipients.

Viking Rapidly Advancing Oral And Injectable VK2735 For Obesity

 
• By 

In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.